Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for antibody inventions
UPC Court of Appeal tackles broad functional antibody claims (UPC_CoA_529/2024) UPC Court of Appeal tackles broad functional antibody claims (UPC_CoA_529/2024) Reviewed by Dr Rose Hughes on Monday, December 01, 2025 Rating: 5
EPO pharma case law trends 2025: Antibodies and biologics EPO pharma case law trends 2025: Antibodies and biologics Reviewed by Dr Rose Hughes on Monday, November 17, 2025 Rating: 5
Patentee's own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23) Patentee's own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23) Reviewed by Dr Rose Hughes on Wednesday, October 22, 2025 Rating: 5
Event report: C5 Pharma & Biotech Patent Litigation in Europe (Day 1), Plausibility, UPC and antibody IP strategy Event report: C5 Pharma & Biotech Patent Litigation in Europe (Day 1), Plausibility, UPC and antibody IP strategy Reviewed by Dr Rose Hughes on Tuesday, May 27, 2025 Rating: 5
UPC takes strong stance on therapeutic antibody inventions (Sanofi v Amgen, UPC_CFI_1/2023) UPC takes strong stance on therapeutic antibody inventions (Sanofi v Amgen, UPC_CFI_1/2023) Reviewed by Dr Rose Hughes on Thursday, July 18, 2024 Rating: 5
US Supreme Court decision in Amgen v Sanofi: The European Perspective US Supreme Court decision in Amgen v Sanofi: The European Perspective Reviewed by Dr Rose Hughes on Wednesday, May 31, 2023 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.